Second Amendment to the Collaboration and License Agreement between Lyell Immunopharma, Inc. and GlaxoSmithKline Intellectual Property (No.5) Limited [*]License Agreement • March 29th, 2022 • Lyell Immunopharma, Inc. • Pharmaceutical preparations • Delaware
This Second Amendment to the Collaboration and License Agreement (the “Second Amendment”) is dated as of 16th December 2021 (the “2nd Amendment Effective Date”), by and between Lyell Immunopharma, Inc. having a principal office at 201 Haskins Way, South San Francisco, California 94080, USA (“Lyell”) and GlaxoSmithKline Intellectual Property (No.5) Limited, a company registered in England and Wales (registered number 11959399) with a registered office at 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom (“GSK”). Lyell and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties”).
